Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study
to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely
exacerbated schizophrenia. To determine whether LB-102 administered to patients with acutely
exacerbated schizophrenia demonstrates antipsychotic efficacy, as determined by a change from
Baseline on the Positive and Negative Syndrome Scale (PANSS) total score, compared to placebo
at 28 days. The secondary objectives of the study are to evaluate improvement in CGI-S,
safety and tolerability, and pharmacokinetics.